Balance Sheet
Cash Flow Statement
Amortization of Deferred ChargesAmortizatization of IntangiblesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashDepreciation & Amortization (CF)Depreciation and DepletionFree Cash FlowGains from Investment SecuritiesGains from Sales and DivestituresNet Cash FlowNet IncomeNon-cash ItemsOther Working Capital ChangesOther financing activitiesShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Compass Therapeutics (CMPX) Change in Account Payables (2023 - 2025)

Compass Therapeutics (CMPX) has disclosed Change in Account Payables for 3 consecutive years, with -$1.5 million as the latest value for Q4 2025.

  • Quarterly Change in Account Payables fell 217.15% to -$1.5 million in Q4 2025 from the year-ago period, while the trailing twelve-month figure was -$664000.0 through Dec 2025, up 63.93% year-over-year, with the annual reading at -$664000.0 for FY2025, 63.93% up from the prior year.
  • Change in Account Payables hit -$1.5 million in Q4 2025 for Compass Therapeutics, down from $500000.0 in the prior quarter.
  • In the past five years, Change in Account Payables ranged from a high of $1.8 million in Q4 2023 to a low of -$3.2 million in Q1 2024.
  • Historically, Change in Account Payables has averaged -$149750.0 across 3 years, with a median of $53000.0 in 2024.
  • Biggest YoY gain for Change in Account Payables was 315.52% in 2025; the steepest drop was 217.15% in 2025.
  • Year by year, Change in Account Payables stood at $1.8 million in 2023, then decreased by 27.75% to $1.3 million in 2024, then tumbled by 217.15% to -$1.5 million in 2025.
  • Business Quant data shows Change in Account Payables for CMPX at -$1.5 million in Q4 2025, $500000.0 in Q3 2025, and $1.0 million in Q2 2025.